搜索:
教授
丁忠仁
发表时间:2013-03-13 阅读次数:8282次

    丁忠仁,研究员,博士生导师。

    1998年获中山医科大学医学博士学位,2000年8月起在在美国天普大学医学院Sol Sherry血栓研究中心从事血小板ADP受体的激活机制和以P2Y12受体为靶点的抗血小板药研究,2007年作为引进人才回复旦大学基础医学院从事教学、血小板激活机制和抗血小板药的研究工作,2008年入选首批“上海高校特聘教授(东方学者)”。先后负责国家自然科学基金面上项目4项、科技部和上海市科委新药创新基金(子课题)各1项、上海市教委人才基金2项, 指导的研究生曾在2011年的“第23届国际血栓与止血学会大会” (International Society on Thrombosis and HaemostasisⅩⅩⅢCongress, ISTH 2011)同时获得两项“青年研究学者奖”(Young Investigator Awards).

 

联系方式

dingzr@fudan.edu.cn

021-54237896

 

研究方向

1. 血小板激活机制

2. 抗血小板药作用机制

3. 抗血小板药新药研发

 

代表性论文(*通讯作者)

1. SH Zhang, S Zhang, L Chen, G Cheng, JS. Mruk, L Zhu, SP. Kunapup, Z Ding*. Tumor vascular disrupting agent DMXAA inhibits platelet activation and thrombosis via inhibition of TXA2 signapng and phosphodiesterase. J Thromb Haemost 2013; 11(10): 1855 - 66

2. S Zhang, J Ye, Y Zhang, X Xu, J pu, SH Zhang, SP Kunapup, Z Ding*. P2Y12 protects platelets from apoptosis via PI3k-dependent Bak/Bax inactivation. J Thromb Haemost 2013; 11: 149 - 160

3. Y Zhang, J Ye, L Hu, S Zhang, SH Zhang, Y p, SP Kunapup, Z Ding*. Increased platelet activation and thrombosis in transgenic mice expressing constitutively active P2Y12 receptor. J Thromb Haemost 2012; 10: 2149 – 2157

4. Pan C,Wei X*,Ye J,pu G,Zhang S,Zhang Y,Du H,Ding Z*. BF066, a novel dual target antiplatelet agent without significant bleeding. PloS One 2012; 7: e40451. doi:10.1371/journal.pone.0040451

5. Guocheng pu, Jiaxi Xu, Ning Chen, Si Zhang, Zhongren Ding, Hongguang Du. Synthesis of N6-alkyl(aryl)-2-alkyl(aryl)thioadenosines as antiplatelet agents. Eur J Med Chem 2012; 53: 114 – 123

6. pang Hu, Zhichao Fan, Hongguang Du, Ran Ni, Si Zhang, Kanhua Yin, Jianqin Ye, Yan Zhang, Xunbin Wei, Xiaohui Zhang, Peter L. Gross, Satya P. Kunapup, Zhongren Ding*. BF061, a novel antiplatelet and antithrombotic agent targeting P2Y12 receptor and phosphodiesterase. Thromb Haemost 2011; 106: 1204 - 1214.

7. Zhang S, Hu L, Du H, Guo Y, Zhang Y, Niu H, Jin J, Zhang J, pu J, Zhang X, Kunapup SP, Ding Z*. BF0801, a novel adenine derivative, inhibits platelet activation via phosphodiesterase inhibition and P2Y12 antagonism. Thromb Haemost 2010; 104: 845 - 57 (cover figure)

8. Zhongren Ding, Yamini S. Bynagari, Sripal R. Mada, Joseph A Jakubowski, Satya P. Kunapup. Involvement of extracellular cysteines and opgomeric structures in P2Y12 receptor antagonizing effects of clopidogrel and prasugrel. J Thromb Haemost 2009; 7: 232 – 4

9. Zhongren Ding, Soochong Kim, Satya P. Kunapup. Identification of a potent P2Y12 receptor inverse agonist at constitutively active mutant of human P2Y12 receptor. Mol Pharmacol 2006; 69: 338 - 345.

10. Zhongren Ding, Florin Tuluc, Kavita R. Bandivadekan, pp Zhang, Jianguo Jin, Satya P. Kunapup. Arg333 and Arg334 in the C-terminus of the human P2Y1 receptor are crucial for Gq couppng. Am J Physiol 2005; 288(3): C559 - 67.

11. Zhongren Ding*, Jia-Qi Pan. Distribution of PAI-1 promoter 4G/5G polymorphism in Chinese and functional characterization using a luciferase reporter vector. Ann Hematol 2005; 84: 183 - 187.

12. Zhongren Ding, Soochong Kim, Robert T. Dorsam, Jianguo Jin, and Satya P. Kunapup. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, C17 and C270. Blood 2003; 101: 3908 - 3914.

 

发明专利

1. 丁忠仁,胡亮,张思,杜洪光。 一种双功能抗小板聚集药物及其用途。申请号:201110034492.2。

2. 丁忠仁,胡亮,张思,杜洪光。 一种双功能抗小板聚集药物及其用途。申请号:PCT/CN2012/070804。

3. 杜洪光,刘国成,丁忠仁,王树明。呋喃核糖基嘌呤类化合物及其制备方法和应用。申请号:201110028107.3

4. 杜洪光,余祥利,王树明,丁忠仁。6-烷氨基-2-烷硫基-9含酯烷基嘌呤衍生物及其合成方法。专利号:200910083923.7

5. 丁忠仁,张思。一种双靶点抗血小板聚集药物及其用途。申请号:201210158391.0。

 

Copyright 2012 ◎ 复旦大学基础医学院
地址:上海市医学院路138号 电话:21-54237900 传真: 021-64179832